DCA seizes overpriced medicine, raids Mahabubabad hospital
The Drugs Control Administration, Telangana, on Monday seized overpriced anti-fungal 'ITROZEN-100 Capsules' (Itraconazole 100 mg) at a medical shop in Mancherial. The label showed an MRP of Rs 245 for 10 capsules, against a permissible Rs 187 including 12% GST, an excess of Rs 58, DCA Director-General VB Kamalasan Reddy said. In a separate raid at Nikhma Health Care hospital, Mahabubabad, officials seized drugs including IV fluids stocked without authorisation.
Source
Mahabubabad — health · read the original report ↗
Desk check · compared with the source
What the desk checked (4)
- DCA seized 'ITROZEN-100 Capsules' (Itraconazole 100 mg) at a medical shop in Mancherial for overpricing. — Attributed to an official DCA release quoting Director-General VB Kamalasan Reddy; batch and manufacturer details appear in source.
- Labelled MRP was Rs 245 for 10 capsules against a permissible MRP of Rs 187 (ceiling price Rs 166.7 plus 12% GST), an excess of Rs 58. — All figures appear in the source and are internally consistent with the stated ceiling price of Rs 16.67 per capsule.
- A raid at Nikhma Health Care Pvt. Ltd. Hospital, New Bazar, Mahabubabad, found unauthorised stocking of drugs including IV fluids, violating Schedule K of the Drugs Rules, 1945. — Attributed to DCA officials acting on credible information; no independent confirmation or hospital response in source.
- The hospital sold certain drugs to patients above printed MRP and stocks were seized. — Stated in the official release; no supporting documentation or response from the hospital given.
Analysts’ view opinion
This story bundles two legally distinct problems. The Mancherial seizure is a price-control matter: the DCA's case is that the MRP printed on the label exceeds the ceiling price fixed by the NPPA under the Drugs (Prices Control) Order, 2013 — which means exposure may not stop at the retailer but travel up to the manufacturing and marketing entities. The Mahabubabad hospital raid is a different legal track, turning on alleged unauthorised stocking for sale under Schedule K of the Drugs Rules, 1945, plus selling above the printed MRP, both of which touch licensing obligations.
- Printing an MRP above the notified ceiling price is not merely a commercial lapse; the price-control framework allows recovery of the overcharged amount with interest, though the story does not say any such demand has been issued here.
- Because the excess price appears on the label itself, the retailer may argue he sold at the printed price — fixing where liability actually rests is a core question for the investigation stage.
- In the hospital matter, the central legal issue is where Schedule K's limited allowances for in-patient use end and 'stocking for sale' begins.
- Seizing critical items such as IV fluids can affect patient care, which makes strict compliance with seizure, sampling and notice procedures important as a matter of fair process.
- A seizure is an allegation, not a finding of guilt — likely next steps include show-cause notices, licence suspension or cancellation proceedings, or prosecution, in each of which the parties have a right to be heard.
What to watch — Watch whether action widens to the manufacturer and marketer, whether a recovery demand for the overcharge follows, and whether the hospital receives a show-cause notice on its licence.
These remain the regulator's allegations at this stage; the story does not establish whether anyone has been formally charged, what the firms or the hospital say in response, or what penalty may ultimately apply.
Deep dive
Research brief · 8 facts · 3 dates · exam-readyThe brief
Context
The Drugs Control Administration (DCA), Telangana, enforces drug pricing and licensing laws in the state. Prices of certain essential medicines are capped by the National Pharmaceutical Pricing Authority (NPPA) under the Drugs (Prices Control) Order, 2013, and hospitals/shops must hold authorisation to stock drugs for sale under the Drugs Rules, 1945. On Monday (ahead of a January 7, 2025 release), DCA teams seized an overpriced anti-fungal capsule brand at a Mancherial medical shop and raided a private hospital in Mahabubabad for unauthorised stocking and sale above MRP.
Key facts
- DCA Telangana seized 'ITROZEN-100 Capsules' (Itraconazole Capsules 100 mg) at a medical shop in Mancherial during raids conducted on Monday.
- The label showed MRP of Rs 245 for 10 capsules, against a permissible MRP of Rs 187 including 12% GST — an excess of Rs 58 per 10 capsules.
- Ceiling price fixed by the Central Government, including Wholesale Price Index, is Rs 16.67 per capsule, i.e. Rs 166.7 for 10 capsules.
- Seized batch details: B. No. ARC-042401A, Mfg Dt 04/2024, Exp Dt 03/2026.
- Manufactured by Allcure Remedies LLP, Yamuna Nagar, Haryana, for Healthkey Life Sciences Pvt. Ltd., Jagadhri, Haryana.
- The product is under price control under the Drugs (Prices Control) Order, 2013, with ceiling price fixed by NPPA, Government of India.
- In a separate raid at Nikhma Health Care Pvt. Ltd. Hospital, New Bazar, Mahabubabad Village, DCA detected unauthorised stocking of drugs including IV fluids, violating Schedule K of the Drugs Rules, 1945.
- The Mahabubabad hospital was also found selling certain drugs to patients above the MRP printed on the label; stocks were seized.
Timeline
- Monday (before January 7, 2025)DCA officials raid a medical shop in Mancherial and seize overpriced ITROZEN-100 Capsules; Drugs Inspector T. Chandana conducts the raid.
- Monday (same day)Acting on credible information, DCA raids Nikhma Health Care Pvt. Ltd. Hospital, Mahabubabad; Drugs Inspector S. Umarani conducts the raid and stocks are seized.
- Tuesday, January 7, 2025DCA Director-General VB Kamalasan Reddy announces both actions in an official release in Hyderabad.
Who has a stake
- Drugs Control Administration, Telangana — Enforcement agency conducting raids and seizures for price-control and licensing violations; led by Director-General VB Kamalasan Reddy.
- Patients and consumers — Were charged Rs 58 extra per 10 capsules of an anti-fungal drug and, at the Mahabubabad hospital, prices above printed MRP.
- Allcure Remedies LLP and Healthkey Life Sciences Pvt. Ltd. — Manufacturer and marketer of ITROZEN-100 whose labelled MRP exceeded the ceiling price, a violation of DPCO 2013.
- Nikhma Health Care Pvt. Ltd. Hospital, Mahabubabad — Faces action for unauthorised stocking of drugs including IV fluids and sale above MRP; stocks seized.
- NPPA, Government of India — Fixes ceiling prices under DPCO 2013 that state drug controllers enforce on the ground.
- Drugs Inspectors T. Chandana (Mancherial) and S. Umarani (Mahabubabad) — Field officers who executed the respective raids.
Why it matters
Medicines are a major out-of-pocket expense for Indian households, and ceiling prices under DPCO 2013 are the main shield against overcharging for essential drugs. When labelled MRPs exceed the ceiling price, every buyer across the country pays the excess, making label-level violations more damaging than a single shop's conduct. Hospitals stocking drugs without authorisation and billing above MRP also weaken the licensing safeguards built into the Drugs Rules, 1945.
UPSC angle
Prelims pointers
- Drugs (Prices Control) Order, 2013 governs price control; ceiling prices are fixed by the National Pharmaceutical Pricing Authority (NPPA), Government of India.
- Ceiling price for Itraconazole Capsules 100 mg: Rs 16.67 per capsule (Rs 166.7 for 10); MRP = Ceiling Price + 12% GST = Rs 187 for 10.
- Seized ITROZEN-100 Capsules bore MRP Rs 245 for 10 capsules — an excess of Rs 58.
- Schedule K of the Drugs Rules, 1945 was cited for unauthorised stocking of drugs, including IV fluids, by a hospital.
- Ceiling price revisions factor in the Wholesale Price Index (WPI).
- VB Kamalasan Reddy is Director-General, Drugs Control Administration, Telangana.
Mains framing
The two Telangana raids illustrate how drug price regulation fails at the last mile. Under the Drugs (Prices Control) Order, 2013, the NPPA fixes ceiling prices for scheduled formulations such as Itraconazole 100 mg (Rs 16.67 per capsule, Rs 187 MRP for 10 with 12% GST), yet a brand was found labelled at Rs 245 — meaning the overcharge of Rs 58 was printed at the manufacturing stage rather than improvised at the counter, and would be recovered from every patient who bought the strip. The second case, at a Mahabubabad hospital, shows a different gap: drugs including IV fluids stocked without the authorisation required under Schedule K of the Drugs Rules, 1945, and sold above the printed MRP, pointing to weak oversight of in-house hospital pharmacies where patients have no choice of seller. Implications include higher out-of-pocket health spending and erosion of trust in labelled prices. The way forward suggested by the source's own logic lies in sustained inspector-led surveillance, action against manufacturers and marketers for label violations, and verification of hospital stocking authorisations — with state drug controllers acting as the enforcement arm of centrally fixed prices.
Key terms
- Drugs Control Administration (DCA), Telangana
- State regulator that inspects pharmacies, hospitals and manufacturers for violations of drug laws and price control orders.
- NPPA
- National Pharmaceutical Pricing Authority, Government of India, which fixes ceiling prices of controlled medicines.
- Drugs (Prices Control) Order, 2013
- Order under which scheduled medicines must be sold at or below the government-fixed ceiling price.
- Ceiling Price
- The maximum price fixed for a controlled formulation; MRP equals ceiling price plus applicable GST (12% in this case).
- Schedule K, Drugs Rules, 1945
- Provision dealing with exemptions and conditions for stocking drugs; cited here for unauthorised stocking of drugs for sale.
- Itraconazole 100 mg
- An anti-fungal medicine under price control, sold here under the brand name ITROZEN-100 Capsules.
Practice questions
- Examine how the Drugs (Prices Control) Order, 2013 and the NPPA's ceiling prices are enforced in practice, using recent Telangana DCA actions as illustration.
- Overpricing printed on the label differs from overcharging at the counter. Discuss the regulatory responses each requires.
- Why are hospital-run pharmacies a particular concern for drug price and licensing compliance? Suggest safeguards.
Grounded only in the source report — figures and dates are the source's, not inferred.